<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>司美格鲁肽、度拉糖肽、利拉鲁肽......8 种 GLP-1RA 用法一文汇总 - 文字轨迹</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/2023-07/%E5%8F%B8%E7%BE%8E%E6%A0%BC%E9%B2%81%E8%82%BD_%E5%BA%A6%E6%8B%89%E7%B3%96%E8%82%BD_%E5%88%A9%E6%8B%89%E9%B2%81%E8%82%BD______8_%E7%A7%8D_glp_1ra_%E7%94%A8%E6%B3%95%E4%B8%80%E6%96%87%E6%B1%87%E6%80%BB/"><meta property="og:site_name" content="文字轨迹"><meta property="og:title" content="司美格鲁肽、度拉糖肽、利拉鲁肽......8 种 GLP-1RA 用法一文汇总"><meta property="og:description" content="司美格鲁肽、度拉糖肽、利拉鲁肽……8 种 GLP-1RA 用法一文汇总 by 丁香园 胰高血糖素样肽-1 受体激动剂（GLP-1RA）是一类新型降糖药。GLP-1RA 的发展经历了从短效到长效再到超长效的发展历程。我国目前已上市的有 8 种 GLP-1RA，这些药物有什么特点？在临床中如何使用呢？我们一起来看看。"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2023-07-24T01:42:38+00:00"><meta property="article:modified_time" content="2023-07-24T01:42:38+00:00"><meta property="article:tag" content="Fetched"><meta property="article:tag" content="丁香园"><meta itemprop=name content="司美格鲁肽、度拉糖肽、利拉鲁肽......8 种 GLP-1RA 用法一文汇总"><meta itemprop=description content="司美格鲁肽、度拉糖肽、利拉鲁肽……8 种 GLP-1RA 用法一文汇总 by 丁香园 胰高血糖素样肽-1 受体激动剂（GLP-1RA）是一类新型降糖药。GLP-1RA 的发展经历了从短效到长效再到超长效的发展历程。我国目前已上市的有 8 种 GLP-1RA，这些药物有什么特点？在临床中如何使用呢？我们一起来看看。"><meta itemprop=datePublished content="2023-07-24T01:42:38+00:00"><meta itemprop=dateModified content="2023-07-24T01:42:38+00:00"><meta itemprop=wordCount content="238"><meta itemprop=keywords content="Fetched,丁香园"><meta name=twitter:card content="summary"><meta name=twitter:title content="司美格鲁肽、度拉糖肽、利拉鲁肽......8 种 GLP-1RA 用法一文汇总"><meta name=twitter:description content="司美格鲁肽、度拉糖肽、利拉鲁肽……8 种 GLP-1RA 用法一文汇总 by 丁香园 胰高血糖素样肽-1 受体激动剂（GLP-1RA）是一类新型降糖药。GLP-1RA 的发展经历了从短效到长效再到超长效的发展历程。我国目前已上市的有 8 种 GLP-1RA，这些药物有什么特点？在临床中如何使用呢？我们一起来看看。"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=文字轨迹 rel=home><div class="logo__item logo__text"><div class=logo__title>文字轨迹</div><div class=logo__tagline>故事流淌过的地方</div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>文章</span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>标签</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>关于</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>司美格鲁肽、度拉糖肽、利拉鲁肽......8 种 GLP-1RA 用法一文汇总</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2023-07-24T01:42:38Z>2023-07-24</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/duty/ rel=category>Duty</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#司美格鲁肽度拉糖肽利拉鲁肽8-种-glp-1ra-用法一文汇总-by-丁香园>司美格鲁肽、度拉糖肽、利拉鲁肽&mldr;&mldr;8 种 GLP-1RA 用法一文汇总 by 丁香园</a></li></ul></nav></div></div><div class="content post__content clearfix"><h2 id=司美格鲁肽度拉糖肽利拉鲁肽8-种-glp-1ra-用法一文汇总-by-丁香园>司美格鲁肽、度拉糖肽、利拉鲁肽&mldr;&mldr;8 种 GLP-1RA 用法一文汇总 by 丁香园</h2><div><p data-mpa-powered-by=yiban.io><img data-backh=93 data-backw=546 data-galleryid data-ratio=0.1711111111111111 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxVfV00pLeHHUZViarv1dicDgOagibC7gkSYwndZ6ZiaxARicuIicQyYetNkXKvibFCK1fqgWPuFoLYZMqbg/640?wx_fmt=png" data-type=png data-w=900 src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxVfV00pLeHHUZViarv1dicDgOagibC7gkSYwndZ6ZiaxARicuIicQyYetNkXKvibFCK1fqgWPuFoLYZMqbg/640?wx_fmt=png"></p><p><br></p><p><span>胰高血糖素样肽-1 受体激动剂（GLP-1RA）是一类新型降糖药。GLP-1RA 的发展经历了从短效到长效再到超长效的发展历程。我国目前已上市的有 8 种 GLP-1RA，这些药物有什么特点？在临床中如何使用呢？我们一起来看看。</span></p><p><span><strong><span><br></span></strong></span></p><p><span><strong><span><br></span></strong></span></p><p><span><strong><span>▍ 分类</span></strong></span></p><p><br></p><p><img data-backh=340 data-backw=546 data-galleryid data-ratio=0.6235565819861432 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbn0MZeic1U3LfPZfkOUg82lrPCXLpoLhhU3wPcyPhRIUlQ6ZCJ2rZoiaibg/640?wx_fmt=jpeg" data-type=jpeg data-w=866 src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbn0MZeic1U3LfPZfkOUg82lrPCXLpoLhhU3wPcyPhRIUlQ6ZCJ2rZoiaibg/640?wx_fmt=jpeg"></p><p><span><strong><span><br></span></strong></span></p><p><span><strong><span><br></span></strong></span></p><p><span><strong><span>▍ 药理作用</span></strong><strong><span>[1]</span></strong></span></p><p><br></p><p><span><strong>（1）降糖作用<br></strong></span></p><p><br></p><p><span>降糖疗效：度拉糖肽（高剂量）、司美格鲁肽（注射）> 其他 GLP-1RA</span></p><p><br></p><p><span><strong>（2）减重作用</strong></span></p><p><br></p><p><span>与降糖作用不同，GLP-1RA 用于减重时的剂量应更大。减重效果排序：司美格鲁肽 > 度拉糖肽、利拉鲁肽</span></p><p><br></p><p><span><strong>（3）心血管保护作用</strong></span></p><p><br></p><p><span>目前证据表明，利拉鲁肽、司美格鲁肽、度拉糖肽均具有心血管保护作用。</span></p><p><br></p><p><span><strong>（4）肾脏保护作用</strong></span></p><p><br></p><p><span>目前证据表明度拉糖肽、司美格鲁肽及利拉鲁肽均显示了良好的肾脏保护作用，可作为伴肾功能损害的 T2DM 患者的降糖药物。</span></p><p><br></p><p><span><strong>（5）T2DM 合并非酒精性脂肪性肝病治疗作用</strong></span></p><p><br></p><p><span>目前证据表明，利拉鲁肽、司美格鲁肽被证实对治疗脂肪肝有效，可减缓纤维化进程，且降低心血管风险。</span></p><p><br></p><p><span><strong>（6）多囊卵巢综合征（PCOS）治疗作用</strong></span></p><p><br></p><p><span>在 GLP-1RA 治疗 PCOS 的研究中，目前主要集中于短效艾塞那肽和长效利拉鲁肽。相较于单用二甲双胍，联合使用艾塞那肽或者利拉鲁肽后，PCOS 患者自然妊娠率、月经周期的频率和规律性以及体外受精妊娠率均明显改善。</span></p><p><br></p><p><br></p><p><span><strong><span>▍ 批准适应症</span></strong></span></p><p><br></p><p><span><strong>（1）国内</strong></span></p><p><br></p><p><img data-backh=162 data-backw=544 data-galleryid data-ratio=0.2972582972582973 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnZc80WpcT3EazRHx8rm6O0y6mP8jJjkAlgeJXxG4lh2BicsemGoKIR5Q/640?wx_fmt=png" data-type=png data-w=693 src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnZc80WpcT3EazRHx8rm6O0y6mP8jJjkAlgeJXxG4lh2BicsemGoKIR5Q/640?wx_fmt=png"></p><p><span>表：在中国获批的 GLP-1RA 适应症</span></p><p><span>图片来源：基层应用胰高糖素样肽-1 受体激动剂治疗 2 型糖尿病的指导建议</span></p><p><br></p><p><span>目前我国尚未批准任何 GLP-1RA 减肥的适应证。</span></p><p><br></p><p><span><strong>（2）国外</strong></span></p><p><br></p><p><span>除 2 型糖尿病外，GLP-1RA 还用于其他领域。</span></p><p><br></p><p><span>利拉鲁肽、司美格鲁肽、度拉糖肽注射液：在美国被批准用于降低伴发心血管疾病的成人 2 型糖尿病患者的心血管不良事件发生风险。</span></p><p><br></p><p><span>利拉鲁肽注射液（3.0 mg）和司美格鲁肽注射液（2.4 mg）在美国被批准用于成人体质量管理，主要适用于体质量指数（BMI）≥ 30 kg/m<sup>2</sup> 的患者，或是 BMI ≥ 27 <span>kg/m</span><sup>2</sup> 同时伴有并发症的患者。</span></p><p><br></p><p><span>利拉鲁肽（3.0 mg）是全球第 1 个被美国 FDA 和欧洲 EMA 批准用于减重的 GLP-1RA。</span></p><p><br></p><p><br></p><p><span><strong><span>▍ </span></strong><strong><span>药代动力学特点</span></strong></span></p><p><br></p><p><img data-backh=416 data-backw=546 data-galleryid data-ratio=0.7612903225806451 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnv4k0ibcyp78Z3YWrcUPfTGPvXFg5sF8QGdWlynbZkQvtxFQGJBL5gww/640?wx_fmt=jpeg" data-type=jpeg data-w=775 src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnv4k0ibcyp78Z3YWrcUPfTGPvXFg5sF8QGdWlynbZkQvtxFQGJBL5gww/640?wx_fmt=jpeg"></p><p><span>图片来源：作者整理</span></p><section><br></section><p><br></p><p><br></p><p><span><strong><span>▍ </span></strong><strong><span>用法用量及储存条件 [2]</span></strong></span></p><p><br></p><p><img data-backh=346 data-backw=546 data-galleryid data-ratio=0.6333333333333333 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbn45YFRhPKKRlaPXdJu8fF84aW57BibLK5G6FGGMlKs90MopUcmdxqMlg/640?wx_fmt=jpeg" data-type=jpeg data-w=1080 src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbn45YFRhPKKRlaPXdJu8fF84aW57BibLK5G6FGGMlKs90MopUcmdxqMlg/640?wx_fmt=jpeg"></p><p><span>图片来源：作者整理</span></p><p><br></p><p><br></p><p><span><strong><span>▍ </span></strong><strong><span>特殊人群用药 [1，3]</span></strong></span></p><p><br></p><p><span><strong>（1）儿童及青少年</strong></span></p><p><br></p><p><span>我国尚未批准任何 GLP-1RA 用于治疗 18 岁以下儿童和青少年 T2DM 患者。</span></p><p><br></p><p><span>美国 FDA：2019 年批准利拉鲁肽（1.8 mg）用于治疗 ≥ 10 岁的儿童和青少年 T2DM 患者，利拉鲁肽（3.0 mg）用于 ≥ 12 岁、体质量超过 60 kg 及 BMI ≥ 30 <span>kg/m</span><sup>2 </sup>青少年患者的减重治疗；</span></p><p><br></p><p><span>2021 年 FDA 批准: 司美格鲁肽（2.4 mg）用于初始 BMI 在同年龄段上 95% 级更高的 12 岁及以上儿童患者的慢性体质量管理。</span></p><p><br></p><p><span><strong><span>（2）妊娠或哺乳期妇女</span></strong></span></p><p><br></p><p><span>GLP-1RA 不推荐妊娠妇女或哺乳期中使用。</span></p><p><br></p><p><span><strong>（3）肝、肾功能不全的患者</strong></span></p><p><br></p><p><img data-backh=298 data-backw=546 data-ratio=0.5462962962962963 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnsJUeYJ3W2gYjUFOsrhNsqzgXpCPeRPtrB9vu4Z04LI8FxNIFe222Mg/640?wx_fmt=jpeg" data-type=jpeg data-w=1080 src="https://mmbiz.qpic.cn/mmbiz_jpg/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnsJUeYJ3W2gYjUFOsrhNsqzgXpCPeRPtrB9vu4Z04LI8FxNIFe222Mg/640?wx_fmt=jpeg"></p><p><span>注：a Child-Pugh 肝功能分级：A 级  5～6 分；B 级  7～9 分；C 级  ≥10 分；「√」 推荐使用；「×」 不推荐使用</span></p><p><span>表格内容参考《基层应用胰高糖素样肽-1 受体激动剂治疗 2 型糖尿病的指导建议》；</span></p><p><br></p><p><span><strong>（4）老年患者</strong></span></p><p><br></p><p><span>一项评价利拉鲁肽用于 65 岁以上老年 T2DM 患者的Ⅲ期临床试验的汇总分析显示，与安慰剂相比，利拉鲁肽可显著降低 HbA1c 水平，并且不增加低血糖发生风险。</span></p><p><br></p><p><span>一项评估度拉糖肽治疗老年 T2DM 患者的Ⅲ期临床试验的汇总分析显示，度拉糖肽治疗年龄 &lt; 65 岁和 ≥ 65 岁两个亚组患者 HbA1c 降幅、低血糖发生率、体重降幅及不良反应发生率差异均无统计学意义  。</span></p><p><br></p><p><span>一项 Meta 分析显示，利司那肽联合口服降糖药治疗年龄 ≥ 65 岁的 T2DM 患者，HbA1c 平均降低 0.54%，体重平均下降 0.9 kg，且不增加低血糖风险。</span></p><p><br></p><p><br></p><p><span><strong><span>▍ </span></strong><strong><span>不良反应</span></strong></span></p><p><br></p><p><span>在安全性方面，GLP-1RA 各制剂差异不大。</span></p><p><br></p><p><span>胃肠道反应是最主要的不良反应，如恶心、呕吐及腹泻等，多为轻、中度且为一过性，多数患者可以耐受。</span></p><p><br></p><p><span>GLP-1RA 单独给药的低血糖风险低，仅在与本身具有低血糖风险的降糖药联合使用时，需要考虑适当降低口服给药剂量或停药，或联合低血糖风险较低的其他降糖药。</span></p><p><br></p><p><span>初次使用要注意有无过敏反应，司美格鲁肽、利拉鲁肽、度拉糖肽与人天然 GLP-1 有较高的同源性，较少发生。</span></p><p><br></p><p><span>长期使用要注意有无注射部位反应。</span></p><p><br></p><p><span>胰腺炎和甲状腺不良事件在中国人群中进行的相关研究，未观察到有意义的安全性信号。</span></p><p><br></p><p><br></p><p><span><strong><span>▍ </span></strong><strong><span>相互作用</span></strong></span></p><p><br></p><p><span>GLP-1RA 与其他药物的相互作用可分为药动学及药效学两方面。<br></span></p><p><br></p><p><span><strong>药动学方面</strong>，GLP-1RA 能延缓胃排空，可能影响同时使用的口服药的吸收速率。如：口服司美格鲁肽增加了左甲状腺素钠的吸收，使其血药浓度升高，应谨慎合用，密切监测 T4 水平，调整剂量。</span></p><p><br></p><p><span><strong>药效学方面</strong>，GLP-1RA 单独使用极少发生低血糖，但与其他降糖药物（磺脲类、胰岛素）联用时低血糖的发生风险增加。</span></p><section><section><section><section><section data-role=outer label="edit by 135editor"><section><span><br></span></section><section><span>专业审核 | 田建卿 副主任医师<br></span></section><p><img data-backh=279 data-backw=477 data-galleryid data-ratio=0.5851851851851851 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnB6lYl6K4ka4nu1ymkerXFVPa2cl0GaEPkTibGCQl72y1cNicbrzVqxQw/640?wx_fmt=png" data-type=png data-w=1080 src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxj4hn69tOjIfVGEImTVKbnB6lYl6K4ka4nu1ymkerXFVPa2cl0GaEPkTibGCQl72y1cNicbrzVqxQw/640?wx_fmt=png"></p><section><br></section><section><span>本文首发于丁香园旗下专业平台：丁香园内分泌时间<br>策划 | 戴冬君</span></section><section><br></section></section><p><img data-galleryid data-ratio=0.38425925925925924 data-s=300,640 data-src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxVfV00pLeHHUZViarv1dicDg5UfnLZibyib3RcDicic3yicZHiaZJBwOS9MYgmSd15qoQQYiaIodt4Y26bazg/640?wx_fmt=png" data-type=png data-w=1080 src="https://mmbiz.qpic.cn/mmbiz_png/XsibUvKtQsKxVfV00pLeHHUZViarv1dicDg5UfnLZibyib3RcDicic3yicZHiaZJBwOS9MYgmSd15qoQQYiaIodt4Y26bazg/640?wx_fmt=png"></p></section></section></section></section><section><br></section><section data-role=paragraph><section data-role=paragraph><section data-role=paragraph><section data-role=paragraph><section><section><span>参考文献<span>（上下滑动查看）</span></span></section><section><span>[1] 胰高血糖素样肽‐1 受体激动剂（GLP‐1RA）临床应用医药专家共识</span></section><section><span>[2] 各 GLP-1RA 药品说明书</span></section><section><span>[3] 中华医学会内分泌学分会, 中华医学会糖尿病学分会. 胰高糖素样肽-1(GLP-1) 受体激动剂用于治疗 2 型糖尿病的临床专家共识 [J]. 中华内科杂志, 2020, 59(11):836-846.</span></section><section><span>[4] 基层应用胰高糖素样肽-1 受体激动剂治疗 2 型糖尿病的指导建议</span></section></section></section></section></section></section><section><span></span><br></section><section><section><br></section></section><p><mp-style-type data-value=3></mp-style-type></p></div><hr><a href=https://mp.weixin.qq.com/s/pBboAQOPXwg7BTe1kK1f3Q ,target=_blank rel="noopener noreferrer">原文链接</a></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/fetched/ rel=tag>fetched</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/%E4%B8%81%E9%A6%99%E5%9B%AD/ rel=tag>丁香园</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/2023-07/%E6%9C%80%E4%BD%B320%E5%BC%A0%E7%94%B5%E5%BD%B1%E6%B5%B7%E6%8A%A5/ rel=prev><span class=pager__subtitle>«&#8201;Previous</span><p class=pager__title>最佳20张电影海报</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/2023-07/%E7%AC%AC%E4%B8%80%E4%BD%9C%E8%80%85%E5%8F%91%E8%A1%A8%E5%9C%A8bioinformatics%E6%9D%82%E5%BF%97%E4%B8%8A%E8%AE%BA%E6%96%87%E6%95%B0top10/ rel=next><span class=pager__subtitle>Next&#8201;»</span><p class=pager__title>第一作者发表在Bioinformatics杂志上论文数top10</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Search… name=q aria-label=Search…>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E9%97%B2%E9%B1%BC%E4%B8%8A%E9%82%A3%E4%BA%9B%E9%80%86%E5%A4%A9%E7%9A%84%E6%B5%8B%E5%BA%8F%E4%BB%AA/>闲鱼上那些逆天的测序仪</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E8%AF%B4%E8%B5%B7%E8%BE%9B%E8%8A%B7%E8%95%BE_%E6%88%91%E6%83%B3%E8%B5%B7%E6%97%A9%E5%B9%B4%E4%B8%80%E4%BA%9B%E5%93%81%E5%91%B3_%E7%8B%AC%E7%89%B9_%E7%9A%84%E6%81%90%E6%80%96%E7%89%87/>说起辛芷蕾，我想起早年一些品味“独特”的恐怖片</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E5%A4%9A%E6%AC%A1%E7%94%9F%E5%AD%90%E5%90%8E_28%E5%B2%81%E5%86%9C%E6%9D%91%E6%99%BA%E9%9A%9C%E5%A5%B3%E5%AD%A9%E6%82%84%E7%84%B6%E7%A6%BB%E4%B8%96/>多次生子后，28岁农村智障女孩悄然离世</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/openai%E7%BD%95%E8%A7%81%E5%8F%91%E8%AE%BA%E6%96%87_%E6%88%91%E4%BB%AC%E6%89%BE%E5%88%B0%E4%BA%86ai%E5%B9%BB%E8%A7%89%E7%9A%84%E7%BD%AA%E9%AD%81%E7%A5%B8%E9%A6%96/>OpenAI罕见发论文：我们找到了AI幻觉的罪魁祸首</a></li><li class=widget__item><a class=widget__link href=../../../posts/2025-09/%E5%8D%97%E4%BA%AC%E5%8D%96%E6%B7%AB%E5%A4%B4%E7%9B%AE1_34%E4%BA%BF%E6%B8%AF%E5%85%83%E8%A2%AB%E7%91%9E%E9%93%B6%E5%8E%9F%E5%89%AF%E6%80%BB%E7%9B%91%E7%A7%81%E5%90%9E/>南京卖淫头目1.34亿港元被瑞银原副总监私吞</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/duty/>Duty</a></li><li class=widget__item><a class=widget__link href=../../../categories/duty2/>Duty2</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/cnbeta/ title=Cnbeta>Cnbeta (148)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/datawhale/ title=Datawhale>Datawhale (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/drpei/ title=Drpei>Drpei (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/fetched/ title=Fetched>Fetched (755)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/githubdaily/ title=GitHubDaily>GitHubDaily (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E4%B8%81%E9%A6%99%E5%9B%AD/ title=丁香园>丁香园 (30)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E4%BA%BA%E7%89%A9/ title=人物>人物 (15)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%8D%97%E6%96%B9%E5%91%A8%E6%9C%AB/ title=南方周末>南方周末 (11)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%8F%E4%BC%97%E8%BD%AF%E4%BB%B6/ title=小众软件>小众软件 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%8F%E5%A4%A7%E5%A4%AB%E6%BC%AB%E7%94%BB/ title=小大夫漫画>小大夫漫画 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%B0%91%E6%95%B0%E6%B4%BE/ title=少数派>少数派 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E5%BE%AA%E5%9B%A0%E7%BC%89%E8%8D%AF/ title=循因缉药>循因缉药 (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%96%B0%E4%B9%A1%E5%9C%9F/ title=新乡土>新乡土 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%98%9F%E7%90%83%E5%95%86%E4%B8%9A%E8%AF%84%E8%AE%BA/ title=星球商业评论>星球商业评论 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%9C%88%E5%85%89%E5%8D%9A%E5%AE%A2/ title=月光博客>月光博客 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%9C%AA%E9%97%BBcode/ title=未闻Code>未闻Code (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%A7%BD%E8%BE%B9%E5%BE%80%E4%BA%8B/ title=槽边往事>槽边往事 (9)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%AF%8F%E6%97%A5%E4%BA%BA%E7%89%A9/ title=每日人物>每日人物 (10)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%B5%AA%E6%BD%AE%E5%B7%A5%E4%BD%9C%E5%AE%A4/ title=浪潮工作室>浪潮工作室 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E6%B5%AE%E4%B9%8B%E9%9D%99/ title=浮之静>浮之静 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%81%BC%E8%A7%81/ title=灼见>灼见 (8)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%86%8A%E8%A8%80%E7%86%8A%E8%AF%AD/ title=熊言熊语>熊言熊语 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%94%9F%E4%BF%A1%E6%8A%80%E8%83%BD%E6%A0%91/ title=生信技能树>生信技能树 (10)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%94%9F%E4%BF%A1%E8%8F%9C%E9%B8%9F%E5%9B%A2/ title=生信菜鸟团>生信菜鸟团 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90/ title=知识分子>知识分子 (14)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E7%BD%91%E6%98%93%E6%95%B0%E8%AF%BB/ title=网易数读>网易数读 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B4%A2%E6%96%B0/ title=财新>财新 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B4%A2%E7%BB%8F%E4%B8%89%E5%88%86%E9%92%9F/ title=财经三分钟>财经三分钟 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E8%B5%9B%E5%85%88%E7%94%9F/ title=赛先生>赛先生 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/%E9%83%91%E5%B7%9E%E6%A5%BC%E5%B8%82/ title=郑州楼市>郑州楼市 (32)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2025 文字轨迹.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>